Pyxis Oncology, Inc. (PYXS) stock

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30

$1.58+0.00 (0.00%)

Close on Nov 13, 2026Market cap $131.79MP/E –Yield –

Pyxis Oncology gross margin

Gross margin is gross profit as a percentage of revenue.

Pyxis Oncology's gross margin for the twelve months ending Dec 31, 2024 was 97.1%. For fiscal 2025 it was 82.8%, against 97.1% the year before.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	82.8%	−14.3
FY2024	Dec 31, 2024	97.1%	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q1 FY2024	Mar 31, 2024	97.1%	–

Parsed from the XBRL in Pyxis Oncology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PYXS.

Revenue growth-14.2% · median -87.7%

Operating margin-643.4% · median -676.5%

Net margin-625.7% · median -609.0%

Advertisement
300 × 250

See a number that looks wrong?